Post-Marketing Surveillance of Lenvima in Korean Patients

Eisai

Status: Completed

Conditions: Differentiated Thyroid Carcinoma (DTC)

Study type: Observational

Funder types: Industry

Identifiers

NCT02764554

E7080-M065-502

Details and patient eligibility

About

The purpose of this post-marketing surveillance (PMS) is to observe the safety profile of Lenvima (lenvatinib) in normal clinical practice setting.

Enrollment: 132 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

Participants who meet the following criteria will be eligible for inclusion in the study:

1. Participants with approved indication for lenvatinib in Korea
2. Participants who have written consent for use of personal and medical information for the study purpose

Exclusion criteria

Investigators will refer to approved indications and contraindications regarding exclusion criteria

Trial design

132 participants in 1 patient group

Lenvatinib 4 milligram (mg) and 10 mg capsule

Description:

Participants who are prescribed with Lenvatinib per approved prescribing information of lenvatinib in normal clinical practice setting.